Respiratory Diseases Drugs Global Market Report 2022

Mar 2022| TBR335E| TBRC (Publisher)

Report Highlights

Including: 1) By Type: Pharmaceutical Drugs; Biologics
2) By Drug Type: Anti-Asthmatics And COPD Drugs; Cough And Cold Preparations
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/ Drug Stores; Others
4) By Route Of Administration: Oral; Parenteral; Others
5) By Drug Classification: Branded Drugs; Generic Drugs
6) By Mode Of Purchase: Prescription-Based Drugs; Over-The-Counter Drugs
Covering: Boehringer Ingelheim GmbH; Vertex Pharmaceuticals; AstraZeneca; Pfizer Inc.; GlaxosmithKline; Novartis AG

Respiratory Diseases Drugs Global Market Report 2022 from The Business Research Company covers this critical market and the impact on it from the Covid 19 virus. It provides strategists, marketers and senior management with the critical information they need to assess the increasing demand for respiratory diseases drugs which play a critical role in the treatment of patients with Covid 19.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market is experiencing rapid growth due to the coronavirus and how it is likely to stabilize as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Description:
Where is the largest and fastest growing market for the respiratory diseases drugs market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Respiratory Diseases Drugs Market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider respiratory diseases drugs market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the Covid 19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of Covid 19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The respiratory diseases drugs market section of the report gives context. It compares the respiratory diseases drugs market with other segments of the respiratory diseases drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, respiratory diseases drugs indicators comparison.

 

 

 

Scope

Markets Covered:

  • By Type: Pharmaceutical Drugs; Biologics
  • By Drug Type: Anti-Asthmatics And COPD Drugs; Cough And Cold Preparations
  • By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/ Drug Stores; Others
  • By Route Of Administration: Oral; Parenteral; Others
  • By Drug Classification: Branded Drugs; Generic Drugs
  • By Mode Of Purchase: Prescription-Based Drugs; Over-The-Counter Drugs

Companies Mentioned: Boehringer Ingelheim GmbH; Vertex Pharmaceuticals; AstraZeneca; Pfizer Inc.; GlaxosmithKline

Metrics Covered: Number of Enterprises; Number of Employees

Countries: Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Egypt; Finland; France; Germany; Hong Kong; India; Indonesia; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Nigeria; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; Turkey; UAE; UK; USA; Venezuela; Vietnam

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, respiratory diseases drugs indicators comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

  • Table 1 : Historic Market Growth, Value ($ Billion)
  • Table 2 : Forecast Market Growth, Value ($ Billion)
  • Table 3 : Global Respiratory Diseases Drugs Market, 2021, By Region, Value ($ Billion)
  • Table 4 : Global Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Region
  • Table 5 : Global Respiratory Diseases Drugs Market, Growth And Market Share Comparison, By Region
  • Table 6 : Global Respiratory Diseases Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 7 : Global Respiratory Diseases Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 8 : Global Respiratory Diseases Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 9 : Global Respiratory Diseases Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 10 : Global Respiratory Diseases Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 11 : Global Respiratory Diseases Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 12 : Respiratory Diseases Drugs Market Size, Percentage Of GDP, 2016-2026, Global
  • Table 13 : Per Capita Average Respiratory Diseases Drugs Market Expenditure, 2016-2026, Global
  • Table 14 : Asia-Pacific, Respiratory Diseases Drugs Market, 2021, By Country, Value ($ Billion)
  • Table 15 : Asia-Pacific, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Table 16 : Asia-Pacific, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Table 17 : Per Capita Average Respiratory Diseases Drugs Expenditure, 2016-2026, Asia-Pacific Countries
  • Table 18 : Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2021, Asia-Pacific Countries
  • Table 19 : Asia-Pacific Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 20 : China Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 21 : China Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 22 : Australia Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 23 : Australia Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 24 : Hong Kong Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 25 : India Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 26 : India Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 27 : Indonesia Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 28 : Indonesia Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 29 : Japan Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 30 : Japan Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 31 : Malaysia Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 32 : New Zealand Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 33 : Philippines Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 34 : Singapore Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 35 : South Korea Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 36 : Thailand Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 37 : Vietnam Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 38 : Western Europe, Respiratory Diseases Drugs Market, 2021, By Country, Value ($ Billion)
  • Table 39 : Western Europe, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Table 40 : Western Europe, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Table 41 : Per Capita Average Respiratory Diseases Drugs Expenditure, 2016-2026, Western Europe Countries
  • Table 42 : Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2021, Western Europe Countries
  • Table 43 : Western Europe Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 44 : Austria Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 45 : Belgium Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 46 : Denmark Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 47 : Finland Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 48 : France Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 49 : France Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 50 : Germany Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 51 : Germany Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 52 : Ireland Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 53 : Italy Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 54 : Netherlands Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 55 : Norway Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 56 : Portugal Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 57 : Spain Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 58 : Sweden Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 59 : Switzerland Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 60 : UK Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 61 : UK Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 62 : Eastern Europe, Respiratory Diseases Drugs Market, 2021, By Country, Value ($ Billion)
  • Table 63 : Eastern Europe, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Table 64 : Eastern Europe, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Table 65 : Per Capita Average Respiratory Diseases Drugs Expenditure, 2016-2026, Eastern Europe Countries
  • Table 66 : Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2021, Eastern Europe Countries
  • Table 67 : Eastern Europe Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 68 : Czech Republic Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 69 : Poland Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 70 : Romania Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 71 : Russia Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 72 : Russia Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 73 : North America, Respiratory Diseases Drugs Market, 2021, By Country, Value ($ Billion)
  • Table 74 : North America, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Table 75 : North America, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Table 76 : Per Capita Average Respiratory Diseases Drugs Expenditure, 2016-2026, North America Countries
  • Table 77 : Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2021, North America Countries
  • Table 78 : North America Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 79 : Canada Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 80 : Mexico Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 81 : USA Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 82 : USA Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 83 : South America, Respiratory Diseases Drugs Market, 2021, By Country, Value ($ Billion)
  • Table 84 : South America, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Table 85 : South America, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Table 86 : Per Capita Average Respiratory Diseases Drugs Expenditure, 2016-2026, South America Countries
  • Table 87 : Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2021, South America Countries
  • Table 88 : South America Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 89 : Argentina Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 90 : Brazil Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 91 : Brazil Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 92 : Chile Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 93 : Colombia Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 94 : Peru Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 95 : Venezuela Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 96 : Middle East, Respiratory Diseases Drugs Market, 2021, By Country, Value ($ Billion)
  • Table 97 : Middle East, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Table 98 : Middle East, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Table 99 : Per Capita Average Respiratory Diseases Drugs Expenditure, 2016-2026, Middle East Countries
  • Table 100 : Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2021, Middle East Countries
  • Table 101 : Middle East Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 102 : Saudi Arabia Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 103 : Israel Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 104 : Turkey Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 105 : UAE Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 106 : Africa, Respiratory Diseases Drugs Market, 2021, By Country, Value ($ Billion)
  • Table 107 : Africa, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Table 108 : Africa, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Table 109 : Per Capita Average Respiratory Diseases Drugs Expenditure, 2016-2026, Africa Countries
  • Table 110 : Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2021, Africa Countries
  • Table 111 : Africa Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 112 : Egypt Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 113 : Nigeria Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 114 : South Africa Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Table 115 : Boehringer Ingelheim GmbH Financial Performance
  • Table 116 : Vertex Pharmaceuticals Financial Performance
  • Table 117 : AstraZeneca Financial Performance
  • Table 118 : Pfizer Inc Financial Performance
  • Table 119 : GlaxosmithKline Financial Performance
  • Table 120 : Pharmaceutical Drugs Market Historic and Forecast, 2016-2021, 2021-2026F, 2031F, Growth, By Segment, Value ($ Billion), Global
  • Table 121 : Global Pharmaceutical Drugs Market, 2021, By Region, Value ($ Billion)
  • Table 122 : Global Pharmaceutical Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Region
  • Table 123 : Global Pharmaceutical Drugs Market, 2016-2021, 2021-2026F, 2031F, Segmentation By Type, Value ($ Billion)
  • Table 124 : Global Respiratory Diseases Drugs Market In 2026- Growth Countries
  • Table 125 : Global Respiratory Diseases Drugs Market In 2026- Growth Segments
  • Table 126 : Global Respiratory Diseases Drugs Market In 2026- Growth Strategies
  • Figure 1 : Historic Market Growth, Value ($ Billion)
  • Figure 2 : Forecast Market Growth, Value ($ Billion)
  • Figure 3 : Global Respiratory Diseases Drugs Market, 2021, By Region, Value ($ Billion)
  • Figure 4 : Global Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Region
  • Figure 5 : Global Respiratory Diseases Drugs Market, Growth And Market Share Comparison, By Region
  • Figure 6 : Global Respiratory Diseases Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 7 : Global Respiratory Diseases Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 8 : Global Respiratory Diseases Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 9 : Global Respiratory Diseases Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 10 : Global Respiratory Diseases Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 11 : Global Respiratory Diseases Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 12 : Respiratory Diseases Drugs Market Size, Percentage Of GDP, 2016-2026, Global
  • Figure 13 : Per Capita Average Respiratory Diseases Drugs Market Expenditure, 2016-2026, Global
  • Figure 14 : Asia-Pacific, Respiratory Diseases Drugs Market, 2021, By Country, Value ($ Billion)
  • Figure 15 : Asia-Pacific, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Figure 16 : Asia-Pacific, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Figure 17 : Per Capita Average Respiratory Diseases Drugs Expenditure, 2016-2026, Asia-Pacific Countries
  • Figure 18 : Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2021, Asia-Pacific Countries
  • Figure 19 : Asia-Pacific Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 20 : China Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 21 : China Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 22 : Australia Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 23 : Australia Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 24 : Hong Kong Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 25 : India Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 26 : India Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 27 : Indonesia Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 28 : Indonesia Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 29 : Japan Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 30 : Japan Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 31 : Malaysia Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 32 : New Zealand Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 33 : Philippines Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 34 : Singapore Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 35 : South Korea Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 36 : Thailand Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 37 : Vietnam Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 38 : Western Europe, Respiratory Diseases Drugs Market, 2021, By Country, Value ($ Billion)
  • Figure 39 : Western Europe, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Figure 40 : Western Europe, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Figure 41 : Per Capita Average Respiratory Diseases Drugs Expenditure, 2016-2026, Western Europe Countries
  • Figure 42 : Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2021, Western Europe Countries
  • Figure 43 : Western Europe Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 44 : Austria Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 45 : Belgium Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 46 : Denmark Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 47 : Finland Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 48 : France Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 49 : France Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 50 : Germany Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 51 : Germany Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 52 : Ireland Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 53 : Italy Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 54 : Netherlands Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 55 : Norway Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 56 : Portugal Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 57 : Spain Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 58 : Sweden Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 59 : Switzerland Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 60 : UK Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 61 : UK Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 62 : Eastern Europe, Respiratory Diseases Drugs Market, 2021, By Country, Value ($ Billion)
  • Figure 63 : Eastern Europe, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Figure 64 : Eastern Europe, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Figure 65 : Per Capita Average Respiratory Diseases Drugs Expenditure, 2016-2026, Eastern Europe Countries
  • Figure 66 : Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2021, Eastern Europe Countries
  • Figure 67 : Eastern Europe Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 68 : Czech Republic Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 69 : Poland Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 70 : Romania Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 71 : Russia Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 72 : Russia Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 73 : North America, Respiratory Diseases Drugs Market, 2021, By Country, Value ($ Billion)
  • Figure 74 : North America, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Figure 75 : North America, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Figure 76 : Per Capita Average Respiratory Diseases Drugs Expenditure, 2016-2026, North America Countries
  • Figure 77 : Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2021, North America Countries
  • Figure 78 : North America Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 79 : Canada Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 80 : Mexico Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 81 : USA Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 82 : USA Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 83 : South America, Respiratory Diseases Drugs Market, 2021, By Country, Value ($ Billion)
  • Figure 84 : South America, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Figure 85 : South America, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Figure 86 : Per Capita Average Respiratory Diseases Drugs Expenditure, 2016-2026, South America Countries
  • Figure 87 : Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2021, South America Countries
  • Figure 88 : South America Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 89 : Argentina Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 90 : Brazil Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 91 : Brazil Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 92 : Chile Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 93 : Colombia Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 94 : Peru Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 95 : Venezuela Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 96 : Middle East, Respiratory Diseases Drugs Market, 2021, By Country, Value ($ Billion)
  • Figure 97 : Middle East, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Figure 98 : Middle East, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Figure 99 : Per Capita Average Respiratory Diseases Drugs Expenditure, 2016-2026, Middle East Countries
  • Figure 100 : Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2021, Middle East Countries
  • Figure 101 : Middle East Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 102 : Saudi Arabia Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 103 : Israel Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 104 : Turkey Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 105 : UAE Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 106 : Africa, Respiratory Diseases Drugs Market, 2021, By Country, Value ($ Billion)
  • Figure 107 : Africa, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Country
  • Figure 108 : Africa, Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Growth And Market Share Comparison, By Country
  • Figure 109 : Per Capita Average Respiratory Diseases Drugs Expenditure, 2016-2026, Africa Countries
  • Figure 110 : Asthma Prevalence Rate, Respiratory Diseases Drugs Market, Respiratory Diseases Drugs Market/Asthma Prevalence Rate, 2021, Africa Countries
  • Figure 111 : Africa Respiratory Diseases Drugs Market, Segmentation By Type, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 112 : Egypt Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 113 : Nigeria Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 114 : South Africa Respiratory Diseases Drugs Market, 2016-2021, 2021-2026F, 2031F, Value ($ Billion)
  • Figure 115 : Boehringer Ingelheim GmbH Financial Performance
  • Figure 116 : Vertex Pharmaceuticals Financial Performance
  • Figure 117 : AstraZeneca Financial Performance
  • Figure 118 : Pfizer Inc Financial Performance
  • Figure 119 : GlaxosmithKline Financial Performance
  • Figure 120 : Pharmaceutical Drugs Market Historic and Forecast, 2016-2021, 2021-2026F, 2031F, Growth, By Segment, Value ($ Billion), Global
  • Figure 121 : Global Pharmaceutical Drugs Market, 2021, By Region, Value ($ Billion)
  • Figure 122 : Global Pharmaceutical Drugs Market, 2016-2021, 2021-2026F, 2031F, Historic And Forecast, By Region
  • Figure 123 : Global Pharmaceutical Drugs Market, 2016-2021, 2021-2026F, 2031F, Segmentation By Type, Value ($ Billion)
  • Figure 124 : Global Respiratory Diseases Drugs Market In 2026- Growth Countries
  • Figure 125 : Global Respiratory Diseases Drugs Market In 2026- Growth Segments
  • Figure 126 : Global Respiratory Diseases Drugs Market In 2026- Growth Strategies

The Business Research Company is a market research and intelligence company which excels in company, market and consumer research. It has over 50 research professionals at its offices in India, the UK and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Similar Reports from TBRC (Publisher)

Respiratory Diseases Drugs Global Market Report 2021: COVID 19 Implications and Growth to 2030

  • Date - Feb 2021
  • Code - TBR335D

Including: 1) By Type: Anti-Asthmatics And COPD Drugs; Cough And Cold Preparations
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/ Drug Stores; Others
3) By Route Of Administration: Oral; Parenteral; Others
4) By Drug Classification: Branded Drugs; Generic Drugs
5) By Mode Of Purchase: Prescription-Based Drugs; Over-The-Counter Drugs

Covering: GlaxosmithKline Plc; AstraZeneca Plc; Merck & Co; ...

Respiratory Diseases Drugs Global Market Strategic Briefing 2020: Covid 19 Impact and Recovery

  • Date - Jun 2020
  • Code - TBR335C

Including: Anti-Asthmatics And COPD Drugs; Cough And Cold Preparations

The global respiratory diseases drugs market is expected to remain stagnant from $65.97 billion in 2019 to $65.96 billion in 2020 at a CAGR of -0.01%, despite the economic slowdown across countries owing to the pandemic outbreak. The market is then expected to recover and grow at a CAGR of 4.38% ...

Respiratory Diseases Drugs Global Market Report 2020-30: Covid 19 Implications and Growth

  • Date - May 2020
  • Code - TBR335B

Including: 1) By Type: Anti-Asthmatics And COPD Drugs; Cough And Cold Preparations
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/ Drug Stores; Others
3) By Route Of Administration: Oral; Parenteral; Others
4) By Drug Classification: Branded Drugs; Generic Drugs
5) By Mode Of Purchase: Prescription-Based Drugs; Over-The-Counter Drugs

Covering: GlaxosmithKline Plc; AstraZeneca Plc; Merck & Co; Novartis AG; Johnson & ...

Respiratory Diseases Drugs Global Market Report 2019

  • Date - Jan 2019
  • Code - TBR335A

Including: Anti-Asthmatics And COPD Drugs, Cough And Cold Preparations

Covering: GlaxosmithKline Plc, AstraZeneca Plc, Merck & Co, Novartis AG, Johnson & Johnson

The Business Research Company
Price: $5000

Become a Member

Already a member? Login here.

Have a Question? Ask Us.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS